| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/01/2010 | WO2010036947A2 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof |
| 04/01/2010 | WO2010036702A1 Liquid formulations of bendamustine |
| 04/01/2010 | WO2010036335A1 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject |
| 04/01/2010 | WO2010035806A1 Solid pharmaceutical composition |
| 04/01/2010 | WO2010035656A1 Oral preparation |
| 04/01/2010 | WO2010035327A1 Process for producing soft capsule and apparatus for producing the same |
| 04/01/2010 | WO2010035122A2 Complex consisting of polysaccharide and an hpb |
| 04/01/2010 | WO2010035001A1 Method for preserving polypeptides using a sugar and polyethyleneimine |
| 04/01/2010 | WO2010034901A2 Gel adapted for transmitting ultrasound waves, method for making said gel, and bag containing same |
| 04/01/2010 | WO2010034853A1 Utilization of xylitol or its derivatives for taste-masking chemotherapy drugs of the quinolone-o-naphthyridone carboxylic acid group administrated in food intended for pigs |
| 04/01/2010 | WO2010034837A1 Method of solubilising biologically active compounds |
| 04/01/2010 | WO2010005257A3 Controlled-release pharmaceutical preparation containing nicorandil |
| 04/01/2010 | WO2009139924A3 Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| 04/01/2010 | WO2009115531A3 Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| 04/01/2010 | WO2009094751A8 An anti-cancer cytotoxic monoclonal antibody |
| 04/01/2010 | WO2009083804A3 Improved fibronectin-based binding molecules and their use |
| 04/01/2010 | WO2009037592A3 Triazole-based aminoglycoside-peptide conjugates and methods of use |
| 04/01/2010 | WO2009027697A3 Non-aqueous pharmaceutical compositions |
| 04/01/2010 | US20100081795 Rg1 antibodies and uses thereof |
| 04/01/2010 | US20100081725 Flavor composition or fragrance composition, product containing the flavor composition or fragrance composition, and novel ester compound |
| 04/01/2010 | US20100081711 Cytotoxic agents |
| 04/01/2010 | US20100081640 Pharmaceutical composition |
| 04/01/2010 | US20100081618 Transporters Comprising Spaced Arginine Moieties |
| 04/01/2010 | US20100081609 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
| 04/01/2010 | US20100081202 Process for facilitating nucleic acid transfer |
| 04/01/2010 | US20100080847 Medicinal compositions quickly disintegrating in the oral cavity and process for producing the same |
| 04/01/2010 | US20100080844 Method to enhance an immune response of nucleic acid vaccination |
| 04/01/2010 | US20100080839 Parenteral formulation |
| 04/01/2010 | US20100080829 Lyophilized pharmaceutical compositions and methods of making and using same |
| 04/01/2010 | US20100080823 Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants |
| 04/01/2010 | US20100080820 Preparation of a Therapeutic Composition |
| 04/01/2010 | US20100080798 Kim-1 antagonists and use to modulate immune system |
| 04/01/2010 | US20100080782 Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 04/01/2010 | US20100080773 Orally Bioavailable Lipid-Based Constructs |
| 04/01/2010 | US20100080764 Skin Treatment Systems |
| 04/01/2010 | US20100080759 Method for Forming Nano-bubble |
| 04/01/2010 | DE19943491B4 Verbesserte Komprimate Improved compressed |
| 04/01/2010 | CA2738891A1 Orally-administered agent |
| 04/01/2010 | CA2738477A1 Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis |
| 04/01/2010 | CA2738274A1 Complex consisting of polysaccharide and an hpb |
| 04/01/2010 | CA2738147A1 Solid pharmaceutical composition |
| 04/01/2010 | CA2737880A1 Method for manufacturing soft capsule and apparatus for manufacturing the same |
| 04/01/2010 | CA2737407A1 Method for preserving polypeptides using a sugar and polyethyleneimine |
| 04/01/2010 | CA2736939A1 Method of metronomic dosing with camptothecin prodrugs ( e.g.peg-irinotecan ) |
| 04/01/2010 | CA2735899A1 Liquid formulations of bendamustine |
| 03/31/2010 | EP2168981A2 A Fibrin/Fibrinogen-binding conjugate |
| 03/31/2010 | EP2168973A1 Nucleic acid ligand complexes |
| 03/31/2010 | EP2168602A1 Site-specific pegylated linear salmon calcitonin derivatives |
| 03/31/2010 | EP2168601A1 Spherical mannitol crystal particle |
| 03/31/2010 | EP2168598A1 Method of Treatment Using Ligand-Immunogen Conjugates |
| 03/31/2010 | EP2168593A1 Oral vaccine compositions |
| 03/31/2010 | EP2168579A1 Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation |
| 03/31/2010 | EP2168572A1 New controlled release active agent carrier |
| 03/31/2010 | EP2168571A2 Particles for use in a Pharmaceutical Composition |
| 03/31/2010 | EP2168557A2 Production method of gelatin particles |
| 03/31/2010 | EP2167963A2 Polymeric carriers for immunohistochemistry and in situ hybridization |
| 03/31/2010 | EP2167537A2 Compiled methods for analysing and sorting samples |
| 03/31/2010 | EP2167536A1 Mhc multimers, methods for their generation, labeling and use |
| 03/31/2010 | EP2167528A2 Modified toxins |
| 03/31/2010 | EP2167480A2 Cationic lipids compositions and methods for enhancing immune responses to vaccines |
| 03/31/2010 | EP2167136A2 Molecules for targeting compounds to various selected organs or tissues |
| 03/31/2010 | EP2167135A2 Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| 03/31/2010 | EP2167133A2 Preserving secondary peptide structure |
| 03/31/2010 | EP2167131A1 Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations |
| 03/31/2010 | EP2167118A1 Transmembrane prostatic acid phosphatase |
| 03/31/2010 | EP2167109A2 Material compositions which comprise adult stem cells obtained from exocrine glandular tissue, in particular for use in regenerative medicine, e.g. for restoring injured or damaged myocardial tissue |
| 03/31/2010 | EP2167103A1 Self-assembling amphiphilic polymers as anticancer agents |
| 03/31/2010 | EP2167071A2 A baclofen solution for low-volume therapeutic delivery |
| 03/31/2010 | EP2167037A1 Compositions for delivering a drug |
| 03/31/2010 | EP2167036A1 Compositions for delivering a drug |
| 03/31/2010 | EP2167031A2 Hyperbranched polymers based on cyclodextrins and poly(amidoamines) for the controlled release of insoluble drugs |
| 03/31/2010 | EP1773914B9 Polyamino acids functionalised by hydrophobic grafts bearing an anionic charge and applications thereof, such as therapeutic applications |
| 03/31/2010 | EP1315423B1 A thermo-stable bio-matrix |
| 03/31/2010 | EP1194168B1 Methods and products for manipulating uncoupling protein expression |
| 03/31/2010 | EP1104290B1 Microemulsions as solid dosage forms for oral administration |
| 03/31/2010 | CN101688183A Cancerous disease modifying antibodies |
| 03/31/2010 | CN101687931A an anti-cancer cytotoxic monoclonal antibody |
| 03/31/2010 | CN101687930A Chimeric and humanized anti-CD44 antibodies that mediate cancer cell cytotoxicity |
| 03/31/2010 | CN101687929A Monoclonal antibodies against claudin-18 for treatment of cancer |
| 03/31/2010 | CN101687917A Coupling of antibody polypeptides at the c-terminus |
| 03/31/2010 | CN101687819A Novel preparation for external use |
| 03/31/2010 | CN101687049A Immunocytokines for cancer treatment in combination with chemotherapeutic agents |
| 03/31/2010 | CN101687048A Hydrolysable polymeric FMOC- linker |
| 03/31/2010 | CN101687047A Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production |
| 03/31/2010 | CN101687046A Pharmaceutical liquid composition of botulinum toxin with improved stability |
| 03/31/2010 | CN101687045A Cellulosic fiber compositions having odor control and methods of making and using the same |
| 03/31/2010 | CN101687044A Formulations for the oral administration of therapeutic agents and related methods |
| 03/31/2010 | CN101687043A Coated oral nicotine formulation buffered with amino acid |
| 03/31/2010 | CN101687042A Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| 03/31/2010 | CN101686990A Antiviral agent |
| 03/31/2010 | CN101686976A Stable solid preparation comprising 4,5-epoxymorphinan derivative |
| 03/31/2010 | CN101686956A Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins |
| 03/31/2010 | CN101686949A Nanoparticles comprising a cyclodextrin and a biologically active molecule and uses thereof |
| 03/31/2010 | CN101686946A micellar nanoparticles of chemical substances |
| 03/31/2010 | CN101686940A Method of delivering a protein into a cell |
| 03/31/2010 | CN101686936A Use of a natural polysaccharide gel for production of an injectable formulation for treating joint degeneration |
| 03/31/2010 | CN101686931A Pharmaceutical formulation for the production of chewable tablets and lozenges |
| 03/31/2010 | CN101686911A Vesicle composition and external preparation for skin |
| 03/31/2010 | CN101684177A Folate-conjugated polyethylene glycol polyalkylcyanoacrylate, preparation method and application thereof |
| 03/31/2010 | CN101684174A Amphiphilic biologically degradable polyester comb-grafted copolymer and temperature-sensitive situ-gel system thereof |